Document:

Exhibit 4.16

 

SECOND
AMENDMENT TO LICENSE AGREEMENT

 

THIS
SECOND AMENDMENT TO LICENSE AGREEMENT (the “Second Amendment”) is made as of September 17, 2017 by and between
Dekel Pharmaceuticals Ltd. (the “Licensor” or “Dekel”), and Therapix Biosciences Ltd., (the
“Licensee” or “Therapix”). Licensee, on the one hand, and Licensor, on the other, may each
individually be referred to in this Amendment as a “Party” and collectively referred to in this Amendment as
the “Parties”.

 

WITNESSETH:

 

	WHEREAS	The
                                         Parties have each agreed on the terms of the License Agreement signed as of May 20, 2015,
                                         as amended on August 19, 2015 (the “Agreement”); and

 

	WHEREAS	The
                                         Parties desire and agree to amend the Agreement such that certain future consideration
                                         which may be payable to Licensor will be exchanged for equity of the Licensee, all as
                                         set forth herein;

 

NOW,
THEREFORE, the Parties hereby agree as follows:

 

	1.	The
                                         above recitals are hereby made part of this Amendment.

 

	2.	Unless
                                         expressly provided otherwise, all capitalized terms used and not otherwise defined herein
                                         shall bear the respective meanings ascribed to them in the Agreement.

 

	3.	Effective
                                         as of the Amendment Effective Date, Section 3.3 of the Agreement will be replaced in
                                         its entirety with the following new Section 3.3, such that the rights to receive royalties,
                                         sublicense fees or milestone payments shall be replaced with the right to receive additional
                                         equity, as follows:

 

“3.3Consideration

 

In
full consideration for the rights granted hereunder, Licensor shall be issued 475,000 American Depositary Shares (ADSs) of Therapix,
in consideration for the par value thereof. Licensor may instruct Therapix in writing, to issue part of the foregoing number of
Ordinary Shares to third parties.”

 

	4.	Effective
                                         as of the Amendment Effective Date, Section 3A of the Agreement will be deleted.

 

	5.	This
                                         Second Amendment will enter into effect on the day (the “Amendment Effective
                                         Date”) on which all of the following conditions precedent have been met:

 

		5.1.	Therapix
                                         has obtained the approval of the requisite majority at general meeting of the Company’s
                                         shareholders for this Second Amendment, in accordance with applicable law;

 

		5.2.	Therapix
                                         has closed a financing round following the execution hereof of at least $5,000,000 by
                                         June 30, 2018; and

 

		5.3.	Completion
                                         of appropriate filings with and obtainment of the required approvals of the Israeli Securities
                                         Authority and the TASE (and the Nasdaq or SEC, if required).

 

In
the event that the foregoing conditions precedent for the Amendment Effective Date are not fulfilled by June 30, 2018, the provisions
of this Second Amendment shall terminate and shall not have any further force or effect.

 

		6.	Unless
                                         amended hereby, all provisions of the Agreement shall remain in full force and effect.

 

IN
WITNESS WHEREOF, the parties have caused this Second Amendment to be executed by their duly authorized representatives as
of the date first above written.

 

[Remainder
of page intentionally left blank]

 

    

     

    

 

[Signature
page to Second Amendment to the License Agreement between Dekel and Therapix]

 

	THERAPIX
BIOSCIENCES LTD.
	 	DEKEL
    PHARMACEUTICALS LTD.
	 	 	 
	/s/ Josh Blacher	 	/s/ Ascher Shmulewitz
	Signature
    (By)	 	Signature
    (By)
	 	 	 
	Josh Blacher	 	Ascher
Shmulewitz
	Name	 	Name
	 	 	 
	Chief Financial Officer	 	Chairman
	Title	 	Title
	 	 	 
	September 17, 2017	 	September 17, 2017
	Date	 	Date

 

 

 -
2 -Exhibit 4.18

 

Execution Version

 

Separation Agreement

 

By and between Therapix Biosciences Ltd., 4 Ariel Sharon, Hashachar
Tower, Givatayim, Israel (the “Company”), and Josh Blacher, [*] (the “Employee”),
dated this 19th day of December, 2017.

 

Whereas the Company
and the Employee are parties to an Employment Agreement, dated May 2, 2017 (as amended) (the “Employment Agreement”);
and

 

Whereas the parties
have mutually agreed to part ways and disconnect Employer-Employee relationship in an orderly and agreed upon manner; and

 

Whereas certain
disagreements have arisen between the parties concerning the provisions of the Employment Agreement; and

 

Whereas the parties
hereto wish to settle the aforementioned disagreements amicably.

 

Therefore it is hereby agreed by the parties as follows:

 

		1.	Resignation: Immediately after the mutual execution hereof (the “Execution Date”), the Employee will
submit his written resignation as Chief Financial Officer of the Company. It is understood that following mutual discussions and
agreement between the Company and Employee, it was agreed that the Employee would submit such a letter. The language of any public
notice issued by the Company concerning the resignation of the Employee will be coordinated, to the maximum extent possible under
applicable law, with the Employee.

 

		2.	Discontinue of Employer-Employee relationship: For the avoidance of doubt, Employer-Employee relationship shall disconnect
on the Execution Date. Employee will return to the Company, as soon as practical, but in any event not later than the day of the
abovementioned public notice, any and all documents and materials pertaining to his work with the Company, and any property of
the Company that he may have in his possession.

 

		3.	Salary: The Company will pay Employee the full amount equivalent to three monthly salaries inclusive of all benefits,
as though he were to continue to be employed under the Employment Agreement, through the end of the Notice Period, which is three
months following the Execution Date (the “Notice Amount”) in one lump sum payment not later than January 10,
2018. Any required taxes will be deducted, as required by law.

 

		4.	Bonus: The Employee shall receive two-month of salary in the form of a bonus (“Bonus”). Such Bonus
amount will be paid as soon as practical, but in any event not later than February 19, 2018. Of the Bonus amounts, tax will be
deducted as required by law.

 

		5.	Options: Upon the Execution Date, all of the Employee’s 47,500 stock options that have already been granted to
the Employee shall be deemed fully vested (the “Stock Options”). For the avoidance of doubt, the Employee’s
Stock Options may be exercised within a period of ninety (90) days, which is June 19, 2018.

 

     

     

    

 

Execution Version

 

		6.	Mutual non-disparagement: The Company will not disparage
the Employee or his performance or otherwise take any action that could reasonably be expected to adversely affect the Employee’s
personal or professional reputation. Similarly, the Employee will not disparage the Company or any of its directors, officers,
or employees or otherwise take any action that could reasonably be expected to adversely affect the personal or professional reputation
of the Company or any of its directors, officers, or employees. Nothing herein is to be construed as attempting to impede either
party’s obligation, as applicable, to respond to inquiries required by law.

 

		7.	Continued Obligations: Nothing herein is intended to derogate from the Employee’s obligations under his Employment
Agreement, including with respect to non-competition and/or confidentiality, as set forth in the Employment Agreement.

 

		8.	Mutual Waiver: Other than with respect to the transactions contemplated herein, this agreement constitutes a waiver
of any claim(s) that either party might have, as of the date hereof, against the other party.

 

		9.	Further Waiver and Indemnification by Employee: Employee agrees
and undertakes that the above payments constitute the full, appropriate
and sole consideration for any claims or demands he might have against the Company with respect to his employment period with the
Company; Employee acknowledges and declares, that apart from the aforesaid,
he will not be entitled to any additional consideration or compensation in connection with the period of his employment with the
Company, and; Employee hereby waives all claims, demands or rights against the Company. Employee will hold the Company and any
of its directors, officers, employees and service providers harmless of any damage or liability, relating to any payment or compensation
component that a competent court of law may determine in the future Employee was entitled to under his Employment Agreement and/or
during his employment period with the Company. The Employee undertakes to indemnify each of the above mentioned in respect of any
amount that any of them will be found to be required to pay to Employee relating to any such claims, demands or rights or lawsuit
initiated by him (and/or any one in his stead, in his name or on his behalf). Nothing in this section or the preceding section
is intended to derogate from the Employee’s rights as an option holder or, as applicable, as a shareholder.

 

		10.	THE TERMS OF THIS AGREEMENT ARE AGREED TO IN ALL RESPECTS:

 

In witness whereof, the parties have each set their hand upon
this agreement as a binding document, as of the date first written above.

 

	/s/ Ascher Shmulewitz	 	                 /s/ Josh Blacher
	Therapix Biosciences Ltd.	 	                 Josh Blacher

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00282-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00282-of-00352.parquet"}]]